Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.48 USD | -1.69% | +1.74% | +110.84% |
May. 30 | Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating | MT |
May. 07 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
Business Summary
Number of employees: 274
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Antibody Drug Conjugates
100.0
%
| 210 | 100.0 % | 70 | 100.0 % | -66.86% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ameet Mallik
CEO | Chief Executive Officer | 51 | 22-05-08 |
Jose Carmona
DFI | Director of Finance/CFO | 51 | 22-12-18 |
Mohamed Zaki
CTO | Chief Tech/Sci/R&D Officer | 59 | 23-01-02 |
Chief Tech/Sci/R&D Officer | 55 | 12-07-31 | |
Chief Tech/Sci/R&D Officer | 69 | 22-10-31 | |
Corporate Officer/Principal | 51 | 22-11-16 | |
Kimberly Pope
HRO | Human Resources Officer | 57 | 20-08-16 |
Peter J. Graham
LAW | General Counsel | 57 | 22-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Hug
BRD | Director/Board Member | 65 | 19-05-31 |
Ron Squarer
CHM | Chairman | 57 | 20-03-31 |
Jean Bizzari
BRD | Director/Board Member | 69 | 22-06-30 |
Ameet Mallik
CEO | Chief Executive Officer | 51 | 22-05-08 |
Victor Sandor
BRD | Director/Board Member | 57 | 20-04-26 |
Robert Azelby
BRD | Director/Board Member | 56 | 23-06-13 |
Thomas Pfisterer
BRD | Director/Board Member | 42 | 16-09-30 |
Tyrell J. Rivers
BRD | Director/Board Member | 51 | 18-05-31 |
Viviane Monges
BRD | Director/Board Member | 60 | 21-06-10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 102,453,858 | 76,181,578 ( 74.36 %) | 6,264,720 ( 6.115 %) | 74.36 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+110.84% | 341M | |
+18.15% | 125B | |
+15.27% | 109B | |
-2.23% | 24.74B | |
+3.55% | 22.67B | |
-10.05% | 18.14B | |
-41.04% | 16.67B | |
-12.10% | 16.64B | |
+1.02% | 13.45B | |
+22.90% | 11.32B |
- Stock Market
- Equities
- ADCT Stock
- Company ADC Therapeutics SA